Hepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use.
Hepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use.
复制标题
丙型肝炎治疗和治疗阿片类药物使用障碍的药物可改善积极从事药物滥用的阿片类药物使用障碍患者的健康相关生活质量。
DOI：
10.1016/j.drugpo.2022.103906
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Kott
中科院分区：
文献类型：
--
作者：
Spaderna,Max;Kattakuzhy,Sarah;Kang,SunJung;George,Nivya;Bijole,Phyllis;Ebah,Emade;Eyasu,Rahwa;Ogbumbadiugha,Onyinyechi;Silk,Rachel;Gannon,Catherine;Davis,Ashley;Cover,Amelia;Gayle,Britt;Narayanan,Shivakumar;Pao,Maryland;Kott
背景本研究旨在确定丙型肝炎（HCV）治疗是否能改善阿片类药物使用障碍（OUD）患者的健康相关生活质量（HRQL），以及哪些变量与HCV治疗期间OUD患者的HRQL改善相关。一项观察性研究，198例OUD或阿片类药物滥用患者在研究入组1年内接受HCV治疗，主要终点为持续病毒学应答（SVR）。使用丙型肝炎病毒患者报告结局（HCV-PRO）调查评估HRQL，评分越高表示HRQL越好。在第0天、第12周和第24周进行HCV-PRO调查。混合效应模型研究了哪些变量与第0天至第24周HCV-PRO评分的变化相关。结果患者的中位年龄为57岁，主要是男性（68.2%）和黑人（83.3%）。大多数人报告每天或每天以上吸毒（58.6%）和注射吸毒（75.8%）。第0天和第24周的平均HCV-PRO评分分别为64.0和72.9。第24周的HCV-PRO评分与第0天的评分相比有所改善（8.7; p<0.001）。达到SVR（10.4; p<0.001）和在第24周接受OUD（MOUD）药物治疗（9.5; p<0.001）与HCV-PRO评分改善相关。在第24周时，IDU频率没有下降（8.1; p<0.001）或UDS对阿片类药物（8.0; p<0.001）或可卡因（7.5; p=0.003）呈阳性的患者，HCV-PRO评分增加。促进HCV治愈和MOUD参与的干预措施可以改善OUD患者的HRQL。
BackgroundThis study aims to determine whether Hepatitis C (HCV) treatment improves health-related quality of life (HRQL) in patients with opioid use disorder (OUD) actively engaged in substance use, and which variables are associated with improving HRQL in patients with OUD during HCV treatment.MethodsData are from a prospective, open-label, observational study of 198 patients with OUD or opioid misuse within 1 year of study enrollment who received HCV treatment with the primary endpoint of Sustained Virologic Response (SVR). HRQL was assessed using the Hepatitis C Virus Patient Reported Outcomes (HCV-PRO) survey, with higher scores denoting better HRQL. HCV-PRO surveys were conducted at Day 0, Week 12, and Week 24. A mixed-effects model investigated which variables were associated with changing HCV-PRO scores from Day 0 to Week 24.ResultsPatients had a median age of 57 and were predominantly male (68.2%) and Black (83.3%). Most reported daily-or-more drug use (58.6%) and injection drug use (IDU) (75.8%). Mean HCV-PRO scores at Day 0 and Week 24 were 64.0 and 72.9, respectively. HCV-PRO scores at Week 24 improved compared with scores at Day 0 (8.7; p<0.001). Achieving SVR (10.4; p<0.001) and receiving medications for OUD (MOUD) at Week 24 (9.5; p<0.001) were associated with improving HCV-PRO scores. HCV-PRO scores increased at Week 24 for patients who experienced no decline in IDU frequency (8.1; p<0.001) or had a UDS positive for opioids (8.0; p<0.001) or cocaine (7.5; p=0.003) at Week 24.ConclusionPatients with OUD actively engaged in substance use experience improvement in HRQL from HCV cure unaffected by ongoing substance use. Interventions to promote HCV cure and MOUD engagement could improve HRQL for patients with OUD.